
A study on medicine shortages in the Netherlands found that disease and costs were the two most affected elements, with 30% and 20% of shortages rated high on these elements, respectively. The study used a framework of economic, clinical, and patient outcomes to assess the impact of medicine shortages on patients. Direct impact, represented by alternative product and disease, was rated high for 30% of the shortages, while indirect impact, represented by costs, susceptibility, and number of patients, was rated high for 17% of the shortages. No significant differences in impact scores were found based on product characteristics.
Recent Posts

Mifepristone Safety Study: Ensuring Continued Regulatory Oversight
The mifepristone safety study launched by the FDA in April 2026 is actively collecting high-quality real-world data to determine whether the current Risk Evaluation and Mitigation Strategy (REMS) program still strikes the right balance between clinical benefits and potential harms.
S...

HIV Prevention Access Strategies Through Collaborative Partnerships in South Africa
HIV prevention access strategies have reached a pivotal moment in South Africa with the imminent launch of lenacapavir, a long-acting injectable administered twice yearly. This coordinated effort directly confronts the country’s immense HIV burden, including 7.8 million people living with the vir...

Cancer Productivity Disparities in the Asia-Pacific Region
New research exposes a deepening divide in cancer productivity Asia-Pacific, where middle-income countries face rapidly escalating productivity losses from premature cancer deaths and disability, while high-income economies have begun to stabilise their burdens. Between 2010 and 2022, indirect ec...